Pharma's Post-Pandemic Story To Unlock A Cancer-Free Era
Pharma's Post-Pandemic Story To Unlock A Cancer-Free Era
製藥公司的後疫情故事將開啓無癌時代
Pfizer (NYSE:PFE) and Moderna (NASDAQ:MRNA) did not only earn billions of dollars from their COVID-19 leading products but also rose to fame for saving the world from an unforeseen pandemic. But, in a post-pandemic world, Pfizer and Moderna shares lost about 30% of their respective value over the past year. Yet, these struggling pharma companies are promising to turn the tide with their new long-term focus on oncology. Moreover, smaller companies like Mainz Biomed N.V. (NASDAQ:MYNZ) already broke ground when it comes to revolutionizing cancer treatment.
輝瑞（紐約證券交易所代碼：PFE）和摩德納（納斯達克股票代碼：MRNA）不僅從其 COVID-19 領先產品中獲得了數十億美元的收入，而且還因拯救世界免受不可預見的疫情而聲名鵲起。但是，在大流行後的世界中，輝瑞和Moderna的股票在過去一年中分別下跌了約30％。然而，這些陷入困境的製藥公司承諾通過將新的長期重點放在腫瘤學上來扭轉局面。此外，像美因茲生物醫學公司（納斯達克股票代碼：MYNZ）這樣的小型公司在徹底改變癌症治療方面已經破土動工。
Pfizer might be down, but it is certainly not...
輝瑞可能會倒閉，但...
登入免費觀看全文
登入/註冊
資訊熱榜
更新時間